Furthermore, better efficacy of anti-PD-1/PD-L1 inhibitors has been observed in tumors with a high tumor mutational burden (TMB) [30, 38, 50], which is an additional explanation for their poor efficacy in TGCTs, known to have low TMB [9]. The gene discussed is CD274; the disease is neoplasm.